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INTRODUCTION
von Recklinghausen’s disease (vRd, Neurofibro-
matosis type 1, NF-1) is an autosomal dominant he-
reditary disease due to an alteration in the long arm
of chromosome 17 and has a prevalence of approxi-
mately 1 in 3000 (1). It is characterized by cutaneous
and plexiform neurofibromas and abnormal skin
pigmentation called café au lait spots. vRd patients
are known to have a high frequency of various ma-
lignant diseases (2-4). Malignant peripheral nerve
sheath tumor (MPNST) is the malignant counter-
part to benign soft tissue tumors, such as neurofi-
broma or schwannoma and occurs in about 2-5% of
patients with vRd whilst gastrointestinal stromal tu-
mor (GIST) occurs in about 7% of patients with vRd
(2, 5).
We present a rare case of a 57-year-old male with
vRd affected by MPNST of the left femur and coin-
cidental GIST of the small intestine.
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Abstract :18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT) was
performed to evaluate a left femoral subcutaneous mass in a patient with von Reckling-
hausen’s disease (vRd) that gradually enlarged, causing pain and numbness. The left femo-
ral mass showed intense FDG uptake with the maximum standardized uptake value
(SUVmax) of 9.0. Other subcutaneous masses considered benign and neurogenic in na-
ture also showed FDG uptake (SUVmax around 3 or less), but the degree of FDG uptake
differed considerably from the left femoral mass. This observation suggested that the de-
gree of FDG uptake may be a useful indicator of malignant transformation. Incidentally,
PET/CT also showed an asymptomatic large abdominal mass with intense FDG uptake
(SUVmax 8.8). The abdominal mass was resected and confirmed as gastrointestinal stro-
mal tumor (GIST) of the small intestine. Three months later, the left femoral mass was op-
erated on and pathologically diagnosed as a malignant peripheral nerve sheath tumor
(MPNST). Various malignant diseases are known to occur with high frequency in vRd.
Therefore, vRd patients need to have periodical examinations including PET/CT. We pre-
sent a rare case of a patient with vRd with a MPNST of the left femur and coincidental
GIST of the small intestine. J. Med. Invest. 56 : 76-79, February, 2009
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CASE REPORT
A 57-year-old man suffering vRd since childhood
noticed a subcutaneous mass on his left femur was
gradually becoming enlarged. He complained of pain
and numbness and had a focal fever around the left
femoral mass. Physical examination revealed numb-
ness on the lateral surface of the left femur in the
region supplied by the lateral femoral cutaneous
nerve. He also had other multiple, soft, painless,
subcutaneous masses and café au lait spots on the
trunk. He had a family history of vRd that his mother
and son were also with vRd.
Laboratory findings showed mildly elevated leu-
kocyte counts (12,300/μl) and elevated C-reactive
protein (4.92 mg/dl). No increase was seen in tu-
mor markers such as carcinoembryonic antigen
(CEA) or carbohydrate antigen 19-9 (CA19-9).
18F-fluorodeoxyglucose positron emission tomogra-
phy (18F-FDG PET/CT) was performed to evaluate
the left femoral mass (Fig. 1). 18F-FDG (3.7 MBq/kg
of body weight : 215 MBq) was administered intra-
venously and the scan was obtained 60 minutes af-
ter the injection. The left femoral mass, measuring
5.05.510 cm, showed intense FDG uptake with
the maximum standardized uptake value (SUVmax)
of 9.0 on PET/CT (Fig. 2a). Moderate FDG uptake
was also observed in other subcutaneous masses
(Fig. 3b). Incidentally, PET/CT showed a large ab-
dominal mass measuring 1012 cm with intense
FDG uptake (SUVmax 8.8 ; Fig. 4a). In spite of such
a large abdominal mass, he had no abdominal pain
or constipation.
The patient underwent further radiological stud-
ies. On magnetic resonance imaging (MRI), the left
femoral mass showed hypointensity on T1-weighted
images and hyperintensity on both T2-weighted and
diffusion-weighted images (Fig. 2b, c), with strong
enhancement on post contrast T1-weighted images
(Fig. 2d). Other subcutaneous masses showed simi-
lar intensity to the left femoral mass (Fig. 3c, d).
The large abdominal mass with central decreased
uptake, suggestive of ulcer formation or necrosis,
showed hypointensity on T1-weighted images, hy-
perintensity on both T2 -weighted and diffusion -
weighted images (Fig. 4b). Contrast-enhanced com-
puted tomography showed strong enhancement of
the large abdominal mass (Fig. 4c).
Fig. 1. FDG-PET image (maximum intensity projection im-
age). High uptake of FDG is demonstrated in the left femur (ar-
rows) and intense uptake is also demonstrated in lower abdo-
men (arrowheads).
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Fig. 2. The left femoral mass shows high FDG uptake
(SUVmax 9.0) on a PET/CT image (a) and hyperintensity on
both T2-weighted (b) and diffusion-weighted images (c), with
strong enhancement on a post contrast T1-weighted image (d).
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Consequently, we preoperatively diagnosed the
left femoral mass as a malignant peripheral nerve
sheath tumor (MPNST) and the large abdominal
mass as a tumor of the small intestine, such as
MPNST or gastrointestinal stromal tumor (GIST),
as patients with vRd have a high risk of these tu-
mors which possess generally high- level FDG up-
take.
The abdominal mass was resected and confirmed
as GIST of the small intestine. Three months later,
the left femoral mass was operated and pathologi-
cally diagnosed as MPNST.
DISCUSSION
MPNST with vRd is considered the result of the
malignant transformation of a benign neurogenic
mass such as neurofibroma or schwannoma (6).
Growth tendency, subjective symptoms of pain or
numbness, and local fever have been reported as
good indicators of malignant transformation (6, 7).
In our case, gradual enlargement of the left femoral
mass with pain and numbness and local fever were
suggestive of MPNST as well. The left femoral mass
and other multiple subcutaneous masses showed in-
creased FDG uptake, but the degree of FDG up-
take differed considerably. The former showed high
FDG uptake (SUVmax 9.0) (Fig. 3a), but the latter
showed moderate FDG uptake (SUVmax around 3
or less) (Fig. 3b). The difference of FDG uptake be-
tween the left femoral mass and other subcutaneous
masses in our case suggested that the degree of
FDG uptake could be another useful indicator of
malignant transformation. It is reported that there
is a significant difference in the percent increase in
neurofibroma volume in the following year for le-
sions that had an SUV2 compared with those with
lower values (8).
On the other hand, not only the left femoral
MPNST, but also multiple subcutaneous soft masses
considered benign and neurogenic in nature, showed
similar hyperintensity on diffusion-weighted images
(Fig. 3c, 3d). In our case, it is difficult to distinguish
MPNST from benign neurogenic tumor by means
of diffusion-weighted images.
It is reported that GIST with vRd occurs often in
the small intestine and show a tendency of occurring
in multiple localities (9). In our case, GIST of the
small intestine was noticed unexpectedly. It is known
that various malignant diseases occur with high
frequency in vRd patients (2-4). Therefore, vRd
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Fig. 3. High FDG uptake is observed in the left femoral mass
on a sagittal PET image (a, arrows), whereas moderate FDG up-
take is observed in the other subcutaneous mass considered be-
nign and neurogenic in nature on a sagittal PET image (b, ar-
rows). On diffusion-weighted image, similar hyperintensity is
seen in both the left femoral mass (c, arrows) and the other sub-
cutaneous mass (d, arrows).
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Fig. 4. A large abdominal mass, with central ulcer formation
or necrosis (c, arrow), shows intense FDG uptake (SUVmax
8.8) on PET/CT image (a) and hyperintensity on a T2-weighted
image (b), with strong enhancement on contrast -enhanced com-
puted tomography (c).
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patients need to have periodical examinations, in-
cluding PET/CT.
Although both MPNST and GIST are not rare
with vRd, to our knowledge, there has only been
one case reported of vRd with coincident occurrence
of these tumors (6). We report a case of vRd with
MPNST and GIST. In this case, the asymptomatic
large abdominal mass (GIST) was found incidentally
on PET/CT performed for the evaluation of a left
femoral mass (MPNST). As far as we know, there
has only been one report of vRd with coincident
MPNST and GIST. The degree of FDG uptake may
be a useful indicator of the malignant transformation
of a benign neurogenic mass turning into a malig-
nant tumor (MPNST) in the follow up study.
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